After nearly two decades in the endocrine scene, Crinetics is making its commercial debut with the approval of a game-changing treatment for the rare growth disorder acromegaly. The FDA on Thursday ...

What Is Palsonify, and Why Does It Matter? Palsonify (paltusotine) is a new once-daily oral medicine approved to treat adults with acromegaly who either didn’t get much help from surgery or cannot ...

The FDA just handed this clinical-stage biotech its golden ticket -- but at a $4.3 billion valuation, the market's already pricing in a fair amount of commercial success.

Sept 25 (Reuters) - The U.S. Food and Drug Administration approved Crinetics Pharmaceuticals' (CRNX.O), opens new tab drug to treat a rare hormonal disorder on Thursday, making it the first once-daily ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. SAN DIEGO — Crinetics Pharmaceuticals won Food and Drug Administration approval on ...

SAN DIEGO — Crinetics Pharmaceuticals won Food and Drug Administration approval on Thursday for a drug for a rare and debilitating hormonal disorder — the company’s first approved product. But the ...